To include your compound in the COVID-19 Resource Center, submit it here.

Clovis off as BMS eyes PARP partnership, not M&A

Clovis Oncology Inc. (NASDAQ:CLVS) fell $13.21 (13%) to $84.81 on Monday as investors digested a deal between the biotech and Bristol-Myers Squibb Co. (NYSE:BMY) to run multiple trials with PD-1

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE